Vuno Inc., a South Korean artificial intelligence-powered medical solutions provider, said on Tuesday that Vuno Med-Fundus AI has received marketing license approval from the Taiwan Food and Drug Administration (TFDA).
The AI solution provides major findings for the diagnosis of retinal diseases by locating abnormalities such as drusen, hemorrhage and hard exudate, detecting the abnormalities in fundus images and presenting patient reports.
The AI solution also earned a marketing license from Singapore's Health Sciences Authority (HSA) in September of this year.
Including Fundus AI, Vuno has received TFDA’s marketing approvals for its three medical solutions in a bid to expand its business in the Asia-Pacific region.
It received licenses for Vuno Med-Chest X-ray, which assists in readings of common thoracic abnormalities on chest radiographs and Vuno Med-BoneAge, a diagnostic solution that provides assessments of bone age on hand X-ray images.
In January 2021, Vuno signed an exclusive distributorship agreement with Taiwan’s CHC Healthcare Group for its four AI products, the three solutions with TFDA’s approval and Vuno Med-LungCT AI.
CHC Healthcare, a leading distributor of medical equipment and pharmacy chain operator in Taiwan, is in charge of Vuno products’ local licensing, marketing, promotion and sales.
Write to Ji-Hyun Lee at bluesky@hankyung.com
Jihyun Kim edited this article.
A Koh Young Technology researcher tests its medical robot Kymero Koh Young Technology Inc., a South Korean 3D imagery tech company listed on the Kosdaq, announced on Tuesday that its medical robot Kymero has conducted a total of 100 brain surgeries. The company began developing a medical r
Alchera's SaaS (Software as a Service) allows speedy smoke and fire detection Artificial intelligence-powered image analysis company Alchera Inc. is working with PG&E (The Pacific Gas and Electric Company (PG&E) in the United States to build an early stage detection system for wildfir
(Courtesy of Anymedi Solution) Anymedi Solution Co., South Korea's medical metaverse startup, has applied for a preliminary review of its initial public offering on the junior Kosdaq market, according to investment banking sources on Thursday.Its IPO manager NH Investment & Securities Co. r
South Korea’s first neurosurgery robot, developed by 3D inspection device maker Koh Young Technology Inc., is ready to join the medical robot market, after two leading Korean hospitals wrapped up two-year clinical trials of the new robot.KYMERO is the world’s first commercialization of a